Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Record-Setting REMS: FDA’s Classwide Opioid Program Will Be “Massive”

Executive Summary

FDA is starting the process of developing a classwide Risk Evaluation & Mitigation Strategy for potent opioid drug products - with the resulting program expected to be the most extensive REMS required by the agency since the implementation of the FDA Amendments Act
Advertisement

Related Content

REMS: Added Expense For Pharma, Added Opportunity For Suppliers
FDA Takes Hard Line On Opioid Class REMS: Cooperate, Or Face Withdrawal
FDA Kicks Off Opioid Class REMS Discussion; Asks For Industry Collaboration
King Confident Of Embeda Opioid Approval In 2009; REMS Is The Final Hurdle
REMS: Added Expense For Pharma, Increased Opportunity For Vendors
The Downside Of REMS: An Over-Taxed Health Care System – FDA’s Jenkins
The Downside Of REMS: An Over-Taxed Health Care System – FDA’s Jenkins
ESA Meta-Analysis Underscores Survival Risk
Fluoroquinolone REMS Will Survey Patients, Doctors on Understanding of Risk
REMS Take Effect; FDA Identifies 16 Products With RiskMAPs That Qualify

Topics

Advertisement
UsernamePublicRestriction

Register

PS050698

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel